Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer.

Takatoshi EnomotoA TamiyaK MatsumotoY AdachiK AzumaY InagakiS KounoY TaniguchiN SaijoK OkishioS Atagi

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2020)

No significant benefits were associated with continuation of nivolumab for advanced NSCLC patients. Continuation of nivolumab beyond PD could be a more useful option in patients without new lesions at first PD. Treatment-related toxicities require attention during nivolumab treatment not only before PD but also beyond PD.

Keyphrases

advanced non small cell lung cancer
end stage renal disease
newly diagnosed
ejection fraction
small cell lung cancer
peritoneal dialysis
prognostic factors
epidermal growth factor receptor
combination therapy
working memory
tyrosine kinase